REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune attack on tough cancers: can a combo drug beat the odds?
Disease control OngoingThis study is testing whether adding a new immunotherapy drug (varlilumab) to an existing one (nivolumab) works better than nivolumab alone for patients with aggressive B-cell lymphomas that have come back or stopped responding to standard treatments. The goal is to see if the tw…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Boosting the immune System's cancer fighters: new combo therapy tested for tough lymphomas
Disease control OngoingThis early-stage trial is testing whether adding an investigational drug called NKTR-255 to an approved CAR-T cell therapy makes the treatment more effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. NKTR-255 is designed to boos…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC